Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samples
BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world’s largest prospective studies. The SomaLogic team provided more than 28 million data points from the assay which will be combined with other available genetic, lifestyle, anthropometric and health outcome data to address a range of research questions. This work builds on a successful history of SomaScan® Platform utilization in some of the world’s largest population proteomics biobank projects, including the EPIC, MESA, Fenland, Whitehall II, HUNT3, CRIC, COPD Gene, Spiromics, deCODE and ARIC datasets.
Professor Zhengming Chen, Richard Peto Professor of Epidemiology at Oxford Population Health and UK-Principal Investigator of the China Kadoorie Biobank, said “The large-scale application of proteomics assays in big population biobanks such as CKB will be a game changer. Building on the experience gained in these initial 4,000 samples, we will seek to extend the use of the proteomic assay to a much larger number of samples in the near future.”
The China Kadoorie Biobank (www.ckbiobank.org) was established to investigate the main genetic and environmental causes of common chronic diseases in the Chinese population. Between 2004 and 2008, over 510,000 adults were recruited from ten geographically defined regions of China, with extensive data collection by questionnaire and physical measurements, and with long-term storage of blood samples for future study. All participants are now being monitored for fatal and non-fatal health outcomes through linkage with established registries and health insurance databases in the study areas.
This large, well-established study will be a uniquely powerful and rich resource for investigating the main causes of many common chronic diseases over the next few decades, and the information generated has the potential to improve understanding of disease etiology, risk prediction and development of new treatments. The project is a long-term collaboration between Oxford Population Health, Peking University and the Chinese Academy of Medical Sciences.
SomaLogic’s proprietary SomaScan Platform is designed to be a universal platform that can be applied across research and discovery, translational research and biopharmaceutical development, and clinical applications. SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. The company has run more than 550,000 samples to date.
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com .
About Oxford Population Health
Oxford Population Health (the Nuffield Department of Population Health) is a world-leading research institute, based at the University of Oxford, that investigates the causes and prevention of disease.
We have over 750 staff, students and academic visitors working in a number of world-renowned population health research groups, including the Cancer Epidemiology Unit (CEU), Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), and the National Perinatal Epidemiology Unit (NPEU), and other groups working on public health, health economics, ethics and health record linkage. Oxford Population Health is also a key partner in the Oxford University Big Data Institute.
Forward Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Gilmartin Group LLC
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Orkuveita Reykjavíkur – Green Bond Offering Results29.3.2023 20:44:54 CEST | Press release
Today, March 30th, Orkuveita Reykjavíkur (OR; Reykjavik Energy) concluded a closed green bond offering in series OR020934 GB and OR180255 GB. OR020934 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of September 2nd, 2034. Previously, bonds have been issued with a nominal value of ISK 12,617 million in the category. The series attracted bids totalling ISK 2,160 million nominal value at yields between 3.17% and 3.35%. OR accepted bids amounting to ISK 1,960 million at a yield of 3.24%. OR180255 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of February 18th, 2055. Previously, bonds have been issued with a nominal value of ISK 22,601 million in the category. The series attracted bids totalling ISK 820 million nominal value at yields between 2.99% and 3.15%. OR accepted bids amounting to ISK 620 million at a yield of 3.04%. Fossar Investment Bank oversees the issuance and sale of the b
Medium-term Fiscal Strategy Plan 2024-2028: to counter inflation, safeguard living standards and support growth29.3.2023 20:11:00 CEST | Press release
The government's fiscal strategy plan for the next five years lays out its strategy to utilise fiscal policy in a targeted manner to counter inflation and overheating by increasing expenditure restraint and revenue generation and postponing public investments. At the same time, important basic services that the government has significantly reinforced in recent years are maintained, based on the strong position of the Treasury. Financial support will be provided for those groups least able to withstand the impact of rising inflation, as was done with the government's support actions during the pandemic and the previous year. The Treasury’s fiscal position has improved significantly in recent quarters , and the fiscal outlook for this year appears likely to be better than implied by the most optimistic scenarios of previous projections. Eighteen months ago, the objective was set in the government’s Fiscal policy statement to halt the increase in debt to GDP ratio no later than by year-en
Intervest Offices & Warehouses NV: announces the departure in mutual agreement of Gunther Gielen as CEO29.3.2023 20:05:18 CEST | Press release
The mandate of Gunther Gielen as CEO with Intervest Offices & Warehouses NV ends in mutual agreement and with immediate effect. Attachment PR_GG_ENG
Nokia Corporation: Repurchase of own shares on 29.03.202329.3.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 29 March 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.03.2023 Espoo, Finland – On 29 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL231,0134.39CEUX38,2144.38AQEU9,7344.37TQEX21,5394.39Total300,5004.39 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 a
Zealand Pharma's Annual General Meeting 202329.3.2023 20:00:00 CEST | Press release
Company announcement – No. 9 / 2023 Zealand Pharma's Annual General Meeting 2023 Copenhagen, March 29, 2023 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its Annual General Meeting of 2023 as a partly electronic general meeting. At the meeting, all proposals presented to the General Meeting were adopted. The General Meeting acknowledged the management's report on Zealand's activities in the past financial year and Zealand's audited Annual Report for 2022 was approved. The meeting also approved that the financial result for 2022, which was a loss of TDKK 1,202,135, was carried forward to the next financial year. All the incumbent board members were re-elected as recommended by the Nomination Committee. Hence, Zealand's Board of Directors consists of the following members: Alf Gunnar Martin Nicklasson Kirsten Aarup Drejer Alain MunozJeffrey Berkowitz Michael John Owen Leonard KruimerBernadette Mary Connaughton After the Annual General Meeting, the Boa